| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Entrada Therapeutics, Inc. (TRDA) has 7 insiders with recent SEC Form 4 filings, including 0 buys and 16 sells. TRDA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.96M | $21.01M | - | |
| 10% | 2.96M | $21.01M | - | |
| CEO | 526.0K | $3.73M | - | |
| 10% | 381.3K | $2.70M | - | |
| Pres | 216.3K | $1.53M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 | Sethuraman Natarajan83 | Chief Scientific Officer | Sell | 3,961 | $18.00 | $71,315.82 | -2.3% | -7.9% | -29.4% | |
| Mar 27, 2023 | Doshi Dipal62 | President And CEO | Sell | 2,000 | $14.72 | $29,435.28 | -0.4% | -18.3% | -8.0% | |
| Mar 2, 2023 | Kreher Nerissa54 | Chief Medical Officer | Sell | 1,641 | $10.56 | $17,336.03 | -1.9% | +12.9% | +35.3% | |
| Mar 2, 2023 | Wentworth Kory James61 | Chief Financial Officer | Sell | 1,747 | $10.53 | $18,389.01 | -2.0% | +12.9% | +35.3% | |
| Feb 28, 2023 | Doshi Dipal62 | President And CEO | Sell | 2,000 | $12.00 | $24,000.00 | -1.2% | -13.6% | +1.9% | |
| Jan 27, 2023 | Doshi Dipal62 | President And CEO | Sell | 2,000 | $12.00 | $24,001.00 | -1.2% | +13.6% | +23.0% | |
| Jan 9, 2023 | Doshi Dipal62 | President And CEO | Sell | 2,410 | $15.02 | $36,195.55 | -1.4% | -3.2% | +11.6% | |
| Dec 30, 2022 | Kreher Nerissa54 | Chief Medical Officer | Sell | 5,200 | $13.45 | $69,931.68 | -25.1% | +11.2% | +11.6% | |
| Dec 29, 2022 | Doshi Dipal62 | President And CEO | Sell | 14,590 | $15.02 | $219,119.33 | -2.1% | +4.6% | +6.9% | |
| Dec 8, 2022 | Wentworth Kory James61 | Chief Financial Officer | Sale+OE | 4,550 | $18.95 | $86,237.97 | -21.6% | -45.6% | -32.2% |